Luxury skincare brand Cha Ling has closed all its physical stores in China to optimize its retail strategy as Covid-19 disruptions continue
The LVMH-owned Cha Ling, which operated stores in China for five years, also shut down its WeChat online store.
The brand will continue to sell its products across LVMH’s Sephora China stores as an exclusive brand. It will also retain its Tmall store.
Cha Ling entered China in 2017, a year after it was founded by Laurent Boillot, who is currently CEO of Hennessy.
Since then, the brand has opened three stores in the country: Shanghai HKRI Taikoo Hui, Shanghai IFC, and Hangzhou’s MixC Mall.
The LVMH-owned luxury skincare label is known for blending Eastern and Western cultures through its brand philosophy of "Beauty with a meaning, for you, for the others, and the world."
Cha Ling joins a series of brands closing stores in China, such as L’Oreal-owned beauty brand Maybelline, due to the uncertainty of the Covid-19 situation.


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Thailand Inflation Remains Negative for 10th Straight Month in January
Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Can your cat recognise you by scent? New study shows it’s likely
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 



